Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR4 | Q13639 | 11/20 | 1.00 |
| ▸ | CNR1 | P21554 | 1/20 | 0.46 |
| ▸ | CNR2 | P34972 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL2966179 | 0.99 | HTR4 (0.98) | HTR4CNR1CNR2 | |
| SCHEMBL8295050 | 0.91 | HTR4 (0.83) | HTR4 | |
| SCHEMBL8294944 | 0.90 | HTR4 (0.82) | HTR4 | |
| SCHEMBL8292756 | 0.90 | HTR4 (0.82) | HTR4 | |
| SCHEMBL2967687 | 0.90 | HTR4 (0.81) | HTR4CNR1CNR2 | |
| SCHEMBL2974345 | 0.90 | HTR4 (0.81) | HTR4 | |
| Hydrochloric Acid SCHEMBL2961245 | 0.89 | HTR4 (0.81) | HTR4 | |
| Hydrochloric Acid SCHEMBL2961243 | 0.89 | HTR4 (0.81) | HTR4 | |
| Hydrochloric Acid SCHEMBL2961246 | 0.89 | HTR4 (0.81) | HTR4 | |
| SCHEMBL2964224 | 0.89 | HTR4 (0.82) | HTR4CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2533780-B1 | 5-HT4 RECEPTOR AGONISTS FOR THE TREATMENT OF DEMENTIA | ASKAT INC (JP) | 2017-08-23 | — | — | EP | claimed |
| US-8980922-B2 | 5-HT4 receptor agonists for the treatment of dementia | RAQUALIA PHARMA INC. (JP) | 2015-03-17 | — | — | US | claimed |
| US-20120322826-A1 | 5-HT4 RECEPTOR AGONISTS FOR THE TREATMENT OF DEMENTIA | RQUALIA PHAMRA INC. (JP) | 2012-12-20 | — | — | US | claimed |
| EP-2533780-A1 | 5-HT4 RECEPTOR AGONISTS FOR THE TREATMENT OF DEMENTIA | RaQualia Pharma Inc (JP) | 2012-12-19 | — | — | EP | claimed |
| EP-1664036-B1 | BENZIMIDAZOLONE COMPOUNDS HAVING 5-HT4 RECEPTOR AGONISTIC ACTIVITY | PFIZER (US) | 2011-12-28 | — | — | EP | claimed |
| WO-2011099305-A1 | 5-HT4 RECEPTOR AGONISTS FOR THE TREATMENT OF DEMENTIA | RAQUALIA PHARMA INC. (JP) | 2011-08-18 | — | — | WO | claimed |
| US-20100273794-A1 | Benzimidazolone Compounds Having 5-HT4 Receptor Agonistic Activity | PFIZER INC. (US) | 2010-10-28 | — | — | US | claimed |
| US-7776885-B2 | Benzimidazolone compounds having 5-HT4 receptor agonistic activity | PFIZER, INC. (US) | 2010-08-17 | — | — | US | claimed |
| US-20050148573-A1 | Benzimidazolone compounds having 5-HT4 receptor agonistic activity | PFIZER INC. | 2005-07-07 | — | — | US | claimed |
| EP-2533780-B1 | 5-HT4 RECEPTOR AGONISTS FOR THE TREATMENT OF DEMENTIA | ASKAT INC (JP) | 2017-08-23 | — | — | EP | disclosed |
| US-8980922-B2 | 5-HT4 receptor agonists for the treatment of dementia | RAQUALIA PHARMA INC. (JP) | 2015-03-17 | — | — | US | disclosed |
| US-20120322826-A1 | 5-HT4 RECEPTOR AGONISTS FOR THE TREATMENT OF DEMENTIA | RQUALIA PHAMRA INC. (JP) | 2012-12-20 | — | — | US | disclosed |
| EP-2533780-A1 | 5-HT4 RECEPTOR AGONISTS FOR THE TREATMENT OF DEMENTIA | RaQualia Pharma Inc (JP) | 2012-12-19 | — | — | EP | disclosed |
| EP-1664036-B1 | BENZIMIDAZOLONE COMPOUNDS HAVING 5-HT4 RECEPTOR AGONISTIC ACTIVITY | PFIZER (US) | 2011-12-28 | — | — | EP | disclosed |
| US-7776885-B2 | Benzimidazolone compounds having 5-HT4 receptor agonistic activity | PFIZER, INC. (US) | 2010-08-17 | — | — | US | disclosed |
| US-7776885-B2 | Benzimidazolone compounds having 5-HT4 receptor agonistic activity | PFIZER, INC. (US) | 2010-08-17 | — | — | US | disclosed |
| EP-1664036-A1 | BENZIMIDAZOLONE COMPOUNDS HAVING 5-HT4 RECEPTOR AGONISTIC ACTIVITY | Pfizer, Inc. (US) | 2006-06-07 | — | — | EP | disclosed |
| US-20050148573-A1 | Benzimidazolone compounds having 5-HT4 receptor agonistic activity | PFIZER INC. | 2005-07-07 | — | — | US | disclosed |
| WO-2005021539-A1 | BENZIMIDAZOLONE COMPOUNDS HAVING 5-HT4 RECEPTOR AGONISTIC ACTIVITY | PFIZER JAPAN, INC. (JP) | 2005-03-10 | — | — | WO | disclosed |
| WO-2005021539-A1 | BENZIMIDAZOLONE COMPOUNDS HAVING 5-HT4 RECEPTOR AGONISTIC ACTIVITY | PFIZER JAPAN, INC. (JP) | 2005-03-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120322826-A1 | 5-HT4 RECEPTOR AGONISTS FOR THE TREATMENT OF DEMENTIA | HTR4, HTR5A, HTR1A | HTR4 1/4885CNR1 170/4885CNR2 222/4885 |
| US-20050148573-A1 | Benzimidazolone compounds having 5-HT4 receptor agonistic activity | HTR4, GPR4, HTR5A | HTR4 1/4885CNR1 182/4885CNR2 200/4885 |
| US-20100273794-A1 | Benzimidazolone Compounds Having 5-HT4 Receptor Agonistic Activity | HTR4, GPR4, HTR5A | HTR4 1/4885CNR1 182/4885CNR2 200/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.